190 related articles for article (PubMed ID: 37408395)
1. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
[No Abstract] [Full Text] [Related]
2. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
3. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of Clinicopathologic Features of 9 Cases of
SMARCA4-deficient Non-small Cell Lung Cancer].
Zhao R; Zou Y; Chen H; Chen Y; Liu Y; He M
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):575-582. PubMed ID: 36002194
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
6. Perspectives and Issues in the Assessment of
Armon S; Hofman P; Ilié M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
10. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
Mao R; Liu M; Shu X; Li W; Yan W; Li X
Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
[No Abstract] [Full Text] [Related]
11. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
[TBL] [Abstract][Full Text] [Related]
13. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
14. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
15. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
17. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
18. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
19. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
